TransDigm price target raised to $1,460 from $1,310 at BofA

BofA analyst Ronald Epstein raised the firm’s price target on TransDigm to $1,460 from $1,310 and keeps a Buy rating on the shares after the company reported “yet another quarter of knock-out results.” Despite the beat, a softer than expected commercial aftermarket performance resulted in “an overdone negative market reaction,” argues the analyst, who continues to call TransDigm “a standout performer.”